Shares Magazine
2.88p-0.50 (-14.81%)07 Mar 2025, 16:06
Jump to:
Verici Dx PLC Fundamentals
| Company Name | Verici Dx PLC | Last Updated | 2025-03-07 |
|---|---|---|---|
| Industry | Diagnostics & Research | Sector | Healthcare |
| Shares in Issue | 242.541 m | Market Cap | £6.97 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -$0.05 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.0378 | Debt Equity Ratio | 0.0278 |
| Asset Equity Ratio | 1.2277 | Cash Equity Ratio | 0.7114 |
| Quick Ratio | 4.3445 | Current Ratio | 4.54 |
| Price To Book Value | 0.9111 | ROCE | 0 |
Verici Dx PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Verici Dx PLC Company Financials
| Assets | 2023 | 2022 |
|---|---|---|
| Tangible Assets | $1.36 m | $2.01 m |
| Intangible Assets | $2.09 m | $1.97 m |
| Investments | 0 | 0 |
| Total Fixed Assets | $3.45 m | $3.98 m |
| Stocks | 0 | 0 |
| Debtors | $1.10 m | $177,000.00 |
| Cash & Equivalents | $2.65 m | $9.80 m |
| Other Assets | 0 | 0 |
| Total Assets | $7.44 m | $14.30 m |
| Liabilities | 2023 | 2022 |
|---|---|---|
| Creditors within 1 year | $3.51 m | $2.25 m |
| Creditors after 1 year | $377,000.00 | $544,000.00 |
| Other Liabilities | 0 | 0 |
| Total Liabilities | $3.88 m | $2.80 m |
| Net assets | $3.56 m | $11.51 m |
| Equity | 2023 | 2022 |
|---|---|---|
| Called up share capital | $219,000.00 | $219,000.00 |
| Share Premium | $32.95 m | $32.95 m |
| Profit / Loss | -$8.73 m | -$11.41 m |
| Other Equity | $3.56 m | $11.51 m |
| Preference & Minorities | 0 | 0 |
| Total Capital Employed | $3.56 m | $11.51 m |
| Ratios | 2023 | 2022 |
|---|---|---|
| Debt Ratio | $0.10 | $0.05 |
| Debt-to-Equity | $0.11 | $0.05 |
| Assets / Equity | 1.2277 | 1.2277 |
| Cash / Equity | 0.7114 | 0.7114 |
| EPS | -$0.05 | -$0.07 |
| Cash Flow | 2023 | 2022 |
|---|---|---|
| Cash from operating activities | -$7.16 m | -$10.07 m |
| Cashflow before financing | -$7.19 m | $2.61 m |
| Increase in Cash | -$7.42 m | $1.30 m |
| Income | 2023 | 2022 |
|---|---|---|
| Turnover | $1.01 m | 0 |
| Cost of sales | 0 | 0 |
| Gross Profit | 0 | 0 |
| Operating Profit | -$8.87 m | -$11.46 m |
| Pre-Tax profit | -$8.73 m | -$11.41 m |
Verici Dx PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validationand commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients. |
| Latest Interim Date | 15 Jul 2024 |
| Latest Fiscal Year End Date | 30 May 2024 |
Verici Dx PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2024-02-20 | Mr. Julian Huw Baines MBE | Non-Executive Director,Chairman |
| 2024-05-30 | Sir Ian James Carruthers OBE | Non-Executive Director,Senior Independent Non-Executive Director |
| 2024-05-30 | Mr. James Renwick McCullough | Non-Executive Director |
| 2021-07-01 | Dr. Barbara Murphy | Non-Executive Director |
| 2022-05-25 | Ms. Sara Jane Barrington | Executive Director,Chief Executive Officer |
| 2022-12-07 | Dr. Lorenzo Giovanni Gallon | Non-Executive Director |
Verici Dx PLC Contact Details
| Company Name | Verici Dx PLC |
|---|---|
| Address | 19 Stanwell Road, Avon House, Cardiff, CF64 2EZ |
| Telephone | +44 2920710570 |
| Website | https://www.vericidx.com |
Verici Dx PLC Advisors
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Oxford Nanopore Technologies PLC | 101.70 | 9.47 |
| Greggs PLC | 1,867.00 | 5.96 |
| Urban Logistics Reit PLC | 122.20 | 5.34 |
| Bt Group PLC | 160.25 | 5.15 |
| Metro Bank Holdings PLC | 88.90 | 5.08 |
| Goodwin PLC | 7,120.00 | 4.71 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Melrose Industries PLC | 488.80 | -12.15 |
| Just Group PLC | 147.60 | -9.56 |
| Spire Healthcare Group PLC | 174.80 | -7.32 |
| Burberry Group PLC | 997.60 | -6.77 |
| Babcock International Group PLC | 711.00 | -5.26 |
| Carnival PLC | 1,450.00 | -5.14 |
Risers/fallers data from previous trading day.